Zura Bio’s (ZURA) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Zura Bio (NASDAQ:ZURA) in a research report sent to investors on Wednesday morning,Benzinga reports.

Several other analysts have also issued reports on ZURA. HC Wainwright reaffirmed a “neutral” rating and set a $5.00 price target on shares of Zura Bio in a research report on Monday, November 18th. Chardan Capital cut their target price on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 8th. Piper Sandler reissued an “overweight” rating and set a $26.00 price target on shares of Zura Bio in a research report on Thursday, September 19th. Leerink Partners assumed coverage on Zura Bio in a research report on Monday, November 4th. They issued an “outperform” rating and a $15.00 price objective for the company. Finally, Leerink Partnrs raised Zura Bio to a “strong-buy” rating in a report on Monday, November 4th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $15.80.

Zura Bio Stock Performance

Shares of NASDAQ:ZURA opened at $2.28 on Wednesday. Zura Bio has a 12 month low of $2.00 and a 12 month high of $6.35. The company’s fifty day simple moving average is $3.76 and its 200 day simple moving average is $3.80.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Sell-side analysts expect that Zura Bio will post -0.65 EPS for the current year.

Insider Transactions at Zura Bio

In related news, Director Parvinder Thiara sold 1,001,633 shares of the business’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $2.73, for a total value of $2,734,458.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 22.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zura Bio

A number of hedge funds and other institutional investors have recently modified their holdings of ZURA. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Zura Bio during the third quarter worth about $46,000. AQR Capital Management LLC bought a new position in shares of Zura Bio during the second quarter worth approximately $43,000. SG Americas Securities LLC acquired a new stake in shares of Zura Bio in the third quarter valued at approximately $62,000. Renaissance Technologies LLC boosted its stake in shares of Zura Bio by 51.3% in the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after buying an additional 5,900 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new stake in Zura Bio during the third quarter worth approximately $71,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.